home / stock / lian / lian news

LIAN News and Press, LianBio From 01/03/24

Stock Information
Company Name: LianBio
Stock Symbol: LIAN
Market: NASDAQ
Menu
LIAN LIAN Quote LIAN Short LIAN News LIAN Articles LIAN Message Board
Get LIAN Alerts

News, Short Squeeze, Breakout and More Instantly...
LIAN - BofA downgrades LianBio to underperform, cites pipeline optionality

2024-01-03 09:57:25 ET More on LianBio Johnson & Johnson inks licensing deal with LianBio (update) LianBio confirms buyout offer from Concentra Biosciences Seeking Alpha’s Quant Rating on LianBio Historical earnings data for LianBio Financi...
LIAN - Week In Review: $1.7B Collaboration Between Elpiscience And Astellas Is Final 2023 Deal

2023-12-31 01:55:00 ET Summary Elpiscience Biopharma forms a $1.7 billion collaboration with Astellas Pharma to develop a bispecific macrophage engager. AstraZeneca acquires Gracell Biotech in a deal worth up to $1.2 billion, including a clinical stage CAR-T therapy. Jinan Qil...

LIAN - LianBio assigns rights for NBTXR3 in China and more Asian markets

2023-12-26 03:50:07 ET More on LianBio LianBio confirms buyout offer from Concentra Biosciences LianBio receives buyout offer of $4.30 per share, plus CVR Financial information for LianBio For further details see: LianBio assigns rights for NBTXR3 in Chin...

LIAN - LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets

SHANGHAI, China and PRINCETON, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the company has entered into an agreement with Janssen Ph...
LIAN - LianBio CEO Yizhe Wang resigns, Adam Stone named interim CEO

2023-12-20 08:10:26 ET More on LianBio LianBio confirms buyout offer from Concentra Biosciences LianBio receives buyout offer of $4.30 per share, plus CVR Seeking Alpha’s Quant Rating on LianBio For further details see: LianBio CEO Yizhe Wang resig...

LIAN - LianBio Announces Departure of Chief Financial Officer

SHANGHAI, China and PRINCETON, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yi Larson, Chief Financial Officer, has resigned from LianBio ...

LIAN - LianBio announces departure of CEO Yizhe Wang

2023-12-19 16:18:46 ET More on LianBio LianBio confirms buyout offer from Concentra Biosciences LianBio receives buyout offer of $4.30 per share, plus CVR Seeking Alpha’s Quant Rating on LianBio Historical earnings data for LianBio Financial in...
LIAN - LianBio Announces Departure of Chief Executive Officer

SHANGHAI, China and PRINCETON, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yizhe Wang, Ph.D., Chief Executive Officer has resigned from L...

LIAN - LianBio's Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences

SHANGHAI, China and PRINCETON, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that its Board of Directors (the “Board”) unanimously...

LIAN - Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments

2023-12-03 04:30:00 ET Summary LianBio, a Princeton-Shanghai in-licensing company, received a $465 million buyout offer from Tang Capital Management. Perpetual Medicines, a Shanghai-Boston AI startup, closed an $8 million seed financing to advance its peptide drug discovery platfo...
Previous 10 Next 10